Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $123M | $233M | $418M | $553M | $1.09B | $2.03B | $2.41B | $2.60B | $2.57B | $2.53B |
| Revenue growth | — | 89.4% | 79.1% | 32.4% | 97.7% | 85.8% | 18.4% | 8.1% | -1.3% | -1.5% |
| Gross profit | $91.2M | $172M | $289M | — | — | — | — | — | — | — |
| Gross margin | 74.0% | 73.6% | 69.2% | — | — | — | — | — | — | — |
| Operating income | -$62.7M | -$75.4M | -$70.9M | -$80.4M | -$506M | -$266M | -$13.7B | -$249M | -$1.02B | -$263M |
| Operating margin | -50.9% | -32.3% | -17.0% | -14.5% | -46.3% | -13.1% | -567.3% | -9.6% | -39.7% | -10.4% |
| Net income | -$74.2M | -$107M | -$97.1M | -$98.9M | -$485M | -$429M | -$13.7B | -$220M | -$1.00B | -$200M |
| Net margin | -60.3% | -45.8% | -23.2% | -17.9% | -44.3% | -21.1% | -567.5% | -8.5% | -39.0% | -7.9% |
| EPS (diluted) | -$1.75 | -$1.93 | -$1.47 | -$1.38 | -$5.36 | -$2.73 | -$84.60 | -$1.34 | -$5.87 | -$1.14 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$51.9M | -$34.4M | -$4.86M | $29.9M | -$53.5M | $194M | $189M | $350M | $294M | $294M |
| Capital expenditures | $2.11M | $2.63M | $4.01M | $3.51M | $4.02M | $8.53M | $16.5M | $11.5M | $10.8M | $8.89M |
| Free cash flow | -$54.0M | -$37.1M | -$8.87M | $26.4M | -$57.5M | $185M | $173M | $339M | $283M | $285M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $50.0M | $42.8M | $424M | $514M | $733M | $893M | $918M | $1.12B | $1.30B | $781M |
| Total assets | $304M | $824M | $1.53B | $1.60B | $17.8B | $17.7B | $4.35B | $4.39B | $3.52B | $2.86B |
| Total liabilities | — | — | — | — | — | — | — | $2.07B | $2.03B | $1.47B |
| Long-term debt | $42.4M | — | — | — | — | — | — | — | — | — |
| Shareholders' equity | $231M | $559M | $1.01B | $1.01B | $15.9B | $16.0B | $2.31B | $2.33B | $1.49B | $1.39B |
| Retained earnings | -$205M | -$312M | -$409M | -$508M | -$993M | -$1.42B | -$15.0B | -$15.2B | -$16.2B | -$16.4B |
| Shares (wtd avg diluted) | 46.2M | 61.5M | 70.5M | 71.8M | 90.5M | 157M | 161M | 165M | 171M | 176M |
Every figure is extracted from Teladoc Health, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.